ABVC BioPharma, Inc. (NASDAQ:ABVC – Get Free Report) saw a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 370,000 shares, a drop of 15.0% from the May 31st total of 435,100 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is presently 0.3 days. Currently, 3.7% of the company’s shares are short sold.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ABVC BioPharma stock. Chase Investment Counsel Corp acquired a new position in ABVC BioPharma, Inc. (NASDAQ:ABVC – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned 1.69% of ABVC BioPharma at the end of the most recent quarter. Institutional investors and hedge funds own 11.38% of the company’s stock.
ABVC BioPharma Trading Up 5.0 %
Shares of NASDAQ:ABVC opened at $0.77 on Friday. The company’s fifty day moving average is $0.98 and its 200 day moving average is $1.16. ABVC BioPharma has a 52 week low of $0.67 and a 52 week high of $6.87.
ABVC BioPharma Company Profile
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.
See Also
- Five stocks we like better than ABVC BioPharma
- With Risk Tolerance, One Size Does Not Fit All
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What to Know About Investing in Penny Stocks
- MarketBeat Week in Review – 6/24 – 6/28
- Canada Bond Market Holiday: How to Invest and Trade
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.